Inozyme Pharma Stock Forecast - 4 Period Moving Average
INZY Stock | USD 2.64 0.17 6.05% |
The 4 Period Moving Average forecasted value of Inozyme Pharma on the next trading day is expected to be 2.69 with a mean absolute deviation of 0.22 and the sum of the absolute errors of 12.88. Inozyme Stock Forecast is based on your current time horizon.
Inozyme |
Inozyme Pharma 4 Period Moving Average Price Forecast For the 27th of November
Given 90 days horizon, the 4 Period Moving Average forecasted value of Inozyme Pharma on the next trading day is expected to be 2.69 with a mean absolute deviation of 0.22, mean absolute percentage error of 0.08, and the sum of the absolute errors of 12.88.Please note that although there have been many attempts to predict Inozyme Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Inozyme Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Inozyme Pharma Stock Forecast Pattern
Backtest Inozyme Pharma | Inozyme Pharma Price Prediction | Buy or Sell Advice |
Inozyme Pharma Forecasted Value
In the context of forecasting Inozyme Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Inozyme Pharma's downside and upside margins for the forecasting period are 0.03 and 6.33, respectively. We have considered Inozyme Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the 4 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Inozyme Pharma stock data series using in forecasting. Note that when a statistical model is used to represent Inozyme Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.AIC | Akaike Information Criteria | 110.0085 |
Bias | Arithmetic mean of the errors | 0.1111 |
MAD | Mean absolute deviation | 0.2221 |
MAPE | Mean absolute percentage error | 0.0516 |
SAE | Sum of the absolute errors | 12.88 |
Predictive Modules for Inozyme Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inozyme Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Other Forecasting Options for Inozyme Pharma
For every potential investor in Inozyme, whether a beginner or expert, Inozyme Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Inozyme Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Inozyme. Basic forecasting techniques help filter out the noise by identifying Inozyme Pharma's price trends.Inozyme Pharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inozyme Pharma stock to make a market-neutral strategy. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics with similar companies.
Risk & Return | Correlation |
Inozyme Pharma Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Inozyme Pharma's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Inozyme Pharma's current price.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Inozyme Pharma Market Strength Events
Market strength indicators help investors to evaluate how Inozyme Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inozyme Pharma shares will generate the highest return on investment. By undertsting and applying Inozyme Pharma stock market strength indicators, traders can identify Inozyme Pharma entry and exit signals to maximize returns.
Accumulation Distribution | 49817.34 | |||
Daily Balance Of Power | (0.63) | |||
Rate Of Daily Change | 0.94 | |||
Day Median Price | 2.76 | |||
Day Typical Price | 2.72 | |||
Price Action Indicator | (0.20) | |||
Period Momentum Indicator | (0.17) | |||
Relative Strength Index | 30.66 |
Inozyme Pharma Risk Indicators
The analysis of Inozyme Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Inozyme Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting inozyme stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Mean Deviation | 2.74 | |||
Standard Deviation | 3.61 | |||
Variance | 13.04 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.